![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/MARKSANS.png)
Share the post "Marksans Pharma ‘s Q3 2024-25 Latest News: Profit Grows by 26.64% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 16.33 % in the past year, substantial increase in net sales/revenue by 6.22 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 480.19 %. Marginal increase in other income during this quarter, up by 151.82%. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Marksans Pharma Limited. Notable increase of 26.64 % in net profit Year to Year, Marksans Pharma Limited’s profitability increased by 7.47 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 25.54 % Year to Year. EPS increased by 8.45 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 586.127 Cr | Rs. 641.923 Cr | Rs. 681.846 Cr | + 6.22 % | + 16.33 % |
| Expenses | Rs. 453.11 Cr | Rs. 506.25 Cr | Rs. 543.08 Cr | + 7.28 % | + 19.86 % |
| Operating Profit | Rs. 133.02 Cr | Rs. 135.67 Cr | Rs. 138.77 Cr | + 2.28 % | + 4.32 % |
| OPM % | 22.69 % | 21.13 % | 20.35 % | -0.78 % | -2.34 % |
| Other Income | Rs. 4.8 Cr | Rs. 11.059 Cr | Rs. 27.849 Cr | + 151.82 % | + 480.19 % |
| Interest | Rs. 3.16 Cr | Rs. 2.63 Cr | Rs. 2.67 Cr | + 1.52 % | -15.51 % |
| Depreciation | Rs. 22 Cr | Rs. 19.51 Cr | Rs. 20.69 Cr | + 6.05 % | -5.95 % |
| Profit before tax | Rs. 112.66 Cr | Rs. 124.59 Cr | Rs. 143.26 Cr | + 14.99 % | + 27.16 % |
| Tax % | 26.36 % | 21.54 % | 26.66 % | + 5.12 % | + 0.3 % |
| Net Profit | Rs. 82.97 Cr | Rs. 97.76 Cr | Rs. 105.07 Cr | + 7.48 % | + 26.64 % |
| EPS in Rs | Rs. 1.84 | Rs. 2.13 | Rs. 2.31 | + 8.45 % | + 25.54 % |
Today, we’re looking at Marksans Pharma Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 16.33 %. However, it did see a marginal increase of 6.22 % from the previous quarter. Expenses ticked up slightly by 7.28 % quarter-on-quarter, aligning with the annual rise of 19.86 %. Operating profit, while up 4.32 % compared to last year, faced a quarter-on-quarter increase of 2.28 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -2.34 %, but a shrinkage of -0.78 % sequentially. Other income rose by 151.82 % compared to the last quarter, despite an annual growth of 480.19 %. Interest expenses surged remarkably by 1.52 % from the previous quarter, yet the year-over-year decrease remains at a moderate -15.51 %. Depreciation costs climbed by 6.05 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -5.95 %. Profit before tax grew annually by 27.16 % but saw an increase from the preceding quarter by 14.99 %.
Tax expenses as a percentage of profits increased slightly by 0.3 % compared to last year, with a more notable quarter-on-quarter increase of 5.12 %. Net profit rose by 26.64 % year-on-year but experienced a 7.48 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 25.54 % but a quarterly rise of 8.45 %. In summary, Marksans Pharma Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 586.127 Cr | Rs. 641.923 Cr | Rs. 681.846 Cr | + 6.22 % | + 16.33 % |
| Expenses | Rs. 453.11 Cr | Rs. 506.25 Cr | Rs. 543.08 Cr | + 7.28 % | + 19.86 % |
| Operating Profit | Rs. 133.02 Cr | Rs. 135.67 Cr | Rs. 138.77 Cr | + 2.28 % | + 4.32 % |
| Net Profit | Rs. 82.97 Cr | Rs. 97.76 Cr | Rs. 105.07 Cr | + 7.48 % | + 26.64 % |
| EPS in Rs | Rs. 1.84 | Rs. 2.13 | Rs. 2.31 | + 8.45 % | + 25.54 % |
In reviewing Marksans Pharma Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 16.33 % year-on-year growth, however, there was a minor increase of 6.22 % from the previous quarter. Expenses rose by 19.86 % compared to the previous year, with a 7.28 % increase quarter-on-quarter. Operating Profit surged by 4.32 % annually, and saw a 2.28 % increase from the last quarter.
Net Profit showed yearly increase of 26.64 %, and experienced a 7.48 % increase from the previous quarter. Earnings Per Share (EPS) rose by 25.54 % annually, however rose by 8.45 % compared to the last quarter. In essence, while Marksans Pharma Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/SONALAD.png)
